GSK unveils plan for UK headquarters of new Consumer Healthcare company
For media and investors only
Issued: London UK
- New UK-listed Consumer Healthcare company to build new global campus and innovation centre in Weybridge, UK
- GSK unveils longer-term plan to move to new UK headquarters
GSK today announced proposals for a major new UK-based headquarters and global campus for the new Consumer Healthcare company following separation in 2022, and its long-term plan for the future headquarters of GSK.
New Consumer Healthcare company headquarters to be based in Weybridge, UK
The proposals announced today form part of GSK’s ongoing work to prepare for the separation of the Group into two leading UK-based companies next year – new GSK, a global pharmaceuticals and vaccines company with an R&D approach focused on the science of the immune system, human genetics and advanced technologies, and a world leading Consumer Healthcare company with annual sales of more than £10 billion, including nine global power brands holding category leadership positions.
Under the proposals announced today the new Consumer Healthcare company will build a new campus in Weybridge, UK. This campus will house the global headquarters for the new Consumer Healthcare business, including an innovation centre (made up of R&D laboratories and the Consumer Healthcare Shopper Science lab) and the company’s global support function teams based in the UK. It will be home to around 1,400 employees.
The new Consumer Healthcare company will open its new headquarters at the end of 2024, subject to consultation and planning approvals. Whilst the development of the campus is ongoing, and at the point of separation of the two companies – expected in mid-2022 – Consumer Healthcare teams will leave GSK House in Brentford and will move to a temporary headquarters in Weybridge, at a site close to but separate from the company’s existing facilities in the area.
Brian McNamara, CEO Designate, GSK Consumer Healthcare said: “This investment in a new cutting-edge campus in the UK will bring together our first-in-class teams as we drive towards our ambitions as the world’s leading consumer healthcare company. Today’s announcement is an important step as we prepare for separation, marking an exciting new beginning for New Consumer Healthcare.”
GSK to move to new UK headquarters after separation
Following separation, GSK will move to a new UK headquarters. The company will identify an appropriate site that meets the needs of the new organisation, with the search based in the same area as GSK’s current headquarters, maintaining access to the UK’s world-leading science and innovation hubs; GSK will provide a further update on its new headquarters in mid-2022, and expects to remain at the company’s current headquarters, at GSK House in Brentford, until at least the end of 2023.
About GSK
GSK is a science-led global healthcare company. For further information please visit www.gsk.com/about-us.
About new Consumer Healthcare
Through separation, GSK is creating a new world-leader in Consumer Healthcare. With sales of £10 billion in 2020, the business will serve more than 100 markets, driven by strong brands and innovation, with cutting-edge science and human understanding to deliver better everyday health. With an industry leading portfolio, including nine global brands holding category leadership positions in oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements; significant scale in the US and China; and a further 11 brands each generating more than £100 million in sales, the business is well placed to address consumer needs and drive long term growth.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2020 and any impacts of the COVID-19 pandemic.
